Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - irinotecan hydrochloride trihydrate - solution for infusion - 20 micromol - irinotecan

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

Irska - angleščina - HPRA (Health Products Regulatory Authority)

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan

Irska - angleščina - HPRA (Health Products Regulatory Authority)

hospira uk limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: sorbitol; water for injections; sodium hydroxide; lactic acid; dilute hydrochloric acid - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - - irinotecan hydrochloride injection, usp is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection, usp is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinote

Irska - angleščina - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - irinotecan hydrochloride trihydrate - solution for infusion - 20 micromole(s) - other antineoplastic agents; irinotecan